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From the Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Beech Hill Road, Sheffield S1O 2RX Dialysis and transplantation have revolutionised the management of chronic renal failure. Many patients with end-stage chronic renal failure are surviving for a long time, but there are some penalties attached to this survival, namely the complications associated with prolonged renal failure as well as the side effects of the treatments (drugs, dialysis and transplantation). Major factors which influence the morbidity and mortality of this population include anaemia, accelerated cardiovascular disease, disturbances in gonadal function, hypertension and abnormalities in lipid and skeletal metabolism.
Significant progress has been made in the past few years concerning the pathophysiology and treatment of renal bone disease. This has been due to advances in our understanding of hormone metabolism, particularly that of vitamin D, and of skeletal physiology. Tn addition, large populations of dialysis-or transplant-treated patients have now been studied for more than a decade with the result that the natural history of this bone disease is more clearly understood.
Renal bone disease is a constellation of skeletal abnormalities (Table 1) , none of which is specific for chronic renal failure. These disorders are frequently, though not invariably, found in combination, and consideration of one of these in isolation has obvious limitations. Nevertheless, the emphasis of this review is on the aetiology and management of osteomalacia, but several more thorough and integrated approaches have appeared recently as reviews or proceedings of symposia. '-5 HISTOLOGICAL DEFINITIONS OF OSTEOMALACIA Osteomalacia can have a variety of meanings. The clinician may apply the term to the syndrome associated with vitamin D deficiency, whereas to the bone histologist it implies defective mineralisation of bone. There is, however, a need for precision, even in histological definitions since, for example, a histological characteristic of vitamin D deficiency in man is an increase in the amount of unmineralised bone matrix; but increased amounts of osteoid are also associated with many other disorders with normal or augmented rates of mineralisation. These include An alternative and simpler method of assessing mineralisation is to measure the maximum number of osteoid lamellae visible under polarised light." In hyperparathyroidism the "hyperosteoidosis" is mainly due to an increase in osteoid surfaces (and sometimes an increase in lamellar thickness), rather than to an increase in the number of osteoid lamellae. 6 Another simple method is to measure the thickness of the osteoid seams themselves or to derive this indirectly from the measurement of osteoid area and the bone surface covered by osteoid-the osteoid index (osteoid area divided by surface osteoid x 100). 6 The prevalence of "osteomalacia" according to some of these histological criteria is shown in Fig. 1 deficiency (though it may appear so radiographically because of metaphyseal resorption below the growth plate: Fig. 3 ). These changes are more likely to reflect secondary hyperparathyroidism than vitamin D deficiency.14 Few biochemical findings are characteristic of osteomalacia in chronic renal failure. Plasma concentrations of calcium are lower in chronic renal failure than in health, particularly in children, and may be lower in patients with osteomalacia than those without.'5 These differences are still present in patients on intermittent haemodialysis though the differences are less marked (Fig. 4) .
A proportion of patients with histologically proven osteomalacia have normal or high concentrations of plasma calcium but without evidence of hyperparathyroidism. In such cases, the bone often shows the absence of active-looking bone cells, which is a characteristic of aluminium-induced bone disease (discussed later).
Plasma phosphate concentrations tend to increase as the glomerular filtration rate falls below 30 ml/min. The level of plasma phosphate is also determined by the diet, the use of oral phosphatebinding agents, and the dialysis regimen in patients with end-stage renal failure. Patients with severe chronic renal failure also malabsorb phosphate and this may be the explanation for the osteomalacia and marked hypophosphataemia seen in some patients not taking phosphate-binding agents. Plasma concentrations of phosphate tend to be lower in patients with osteomalacia but osteomalacia cannot be diagnosed from this alone, since the presence of normal or high plasma concentrations do not exclude osteomalacia (Fig. 4) .
Plasma alkaline phosphatase and plasma hydroxyproline are commonly raised in chronic renal failure. An increase in alkaline phosphatase activity may not always be due to an increase in bonederived phosphatase but may be due to increased activities ofthe gut and liver isoenzymes. In population studies, plasma activities of alkaline phosphatase correlate well with histological indices of bone cell activity-for example, osteoblast counts. Hence, alkaline phosphatase activity is usually increased in patients with osteomalacia combined with secondary hyperparathyroidism, but is normal or low in many patients with osteomalacia alone (Fig. 4) .
Since osteomalacia can rarely be diagnosed without histological assessment of bone, studies of its pathogenesis and the assessment of treatment regimens must include the study of biopsy material, and require a critical awareness of the meaning of the histological variables measured. In the past decade the major thrust in vitamin D research has been directed to studies of its metabolism 25-OHD3.1322 The view that lack of 1,25(OH)2-D3 is the major cause of osteomalacia in renal failure may be an oversimplification. Thus not all patients with severe chronic renal failure have osteomalacia, and its incidence does not invariably increase with time on dialysis despite defects in the metabolism of vitamin D. 23 The incidence of osteomalacia varies widely between dialysis units (Fig. 2) 
other than defective production of 1,25(OH)2-D3 must contribute significantly to the osteomalacia of chronic renal failure.
The production of 24,25(OH)2-D3 may also be deficient in renal failure since the kidney has an enzyme system capable of converting 25-OHD3 to this metabolite. In chronic renal failure, plasma concentrations of 24,25(OH)2-D3 are, in some patients, lower than would be predicted from the circulating concentration of 25-OHD3.24 25 Preliminary observations suggest that patients with renal failure and osteomalacia may have the lower concentrations of 24,25(OH)2-D3. 25 The administration of 24,25(OH)2-D3 alone in doses sufficient to restore plasma concentrations to normal has metabolic effects but does not heal osteomalacia (unpublished observations). There is increasing evidence that both 1,25(OH)2-D3 and 24,25(OH)2-D3 are required for the actions of vitamin D on bone to be complete.26 27 However, the relation between decreased synthesis of 24,25(OH)2-D3 and osteomalacia in chronic renal failure will be clarified only when we know whether or not the kidney is the sole site of production of this metabolite (a controversial issue) since nephrectomy does not appear to aggravate renal bone disease.23
Calcium and phosphate metabolism It is possible that the skeletal effects of vitamin D are not dependent upon direct actions of the metabolites on bone itself but are due to consequent changes in the plasma concentration of calcium, phosphate and parathyroid hormone. One of the reasons why this question remains open is the difficulty in studying mineralisation in vitro, while the effects of vitamin D metabolites in vivo are complex.
In many disorders, including renal failure, the level of plasma phosphate appears to be an important determinant of osteomalacia. The concentration of plasma phosphate in dialysis-treated patients has been shown to correlate inversely with the degree of osteomalacia, such that those patients with normal amounts of osteoid have the higher plasma phosphate concentrations (Fig. 6 ).23 It may be relevant that phosphate concentrations in such patients are considerably higher than the upper limit of normal in health, and hyperphosphataemia may therefore protect the patient from osteomalacia, despite defective vitamin D metabolism. If such a protective mechanism exists, hyperphosphataemia may mask the true importance of disturbed vitamin D metabolism in renal bone disease.
The case for the phosphate effect on mineralisation is greater than for calcium. Calcium deficiency in some experimental models leads to osteoporosis rather than to osteomalacia. However, it has been Indeed the failure to respond to 1,25(OH)2-D3 may be one method of separating patients in whom osteomalacia is due to other causes. It is also the impression of many groups that osteomalacia more commonly fails to respond to vitamin D treatment in patients on intermittent haemodialysis that in patients managed conservatively, and this has led to renewed interest in the possibility that disturbances induced by haemodialysis itself may give rise to osteomalacia. The possible role of fluoride has been the most extensively studied. Fluoride accumulates in chronic renal failure during haemodialysis and is deposited in bone. It is also known that high doses in man induce the formation of excessive amounts of osteoid. Several groups have attempted to find a correlation between fluoride and bone disease whereas others have looked at the effects of reducing the fluoride content of the dialysate. However, there is no consensus view to be obtained from the many studies performed3' and it is now recognised that the bone disease attributed to fluoride may have been due to other factors not recognised at the time.
There is an increasing body of evidence that aluminium retention may be an important factor in the pathogenesis of osteomalacia in dialysistreated patients. A form of osteomalacia associated with a high incidence of bone pain and fractures is common in certain geographical locations with a high aluminium content in the water (Fig. 2) , and its incidence appears to decrease with deionisation of the water. There is also a good correlation (in the UK) between osteomalacia associated with fractures and the aluminium content of the water used for dialysis.3233Flendriget al. 34 showed that the incidence of fractures (and of dialysis dementia) in their unit was associated with a source of aluminium in the dialysate lines whereas other patients using the same tap water did not develop this complication. This suggests that either aluminium or some factor associated with aluminium is responsible for the high prevalence of osteomalacia seen in some centres.
The question arises whether or not phosphatebinding agents containing aluminium salts may give rise to aluminium toxicity, since there is good evidence that oral aluminium is absorbed. 35 One of the difficulties of investigating this problem is that skeletal retention of aluminium may remain for many years after the source has been withdrawn and aluminium toxicity may take many years to develop. Thus, it is difficult to assess the relative importance of oral and water-borne aluminium. The evidence to date suggests that water-borne, rather than oral aluminium, is most commonly the major source of Kanis skeletal aluminium.
Acidosis
The role of acidosis in contributing to renal bone disease has been advocated for many years. It has been suggested that bone acts as a buffer by releasing alkaline bone salts and this is supported by the finding of a decrease in the bicarbonate content of bone from uraemic patients. 36 The acute administration of acid loads to normal man results in a negative calcium balance37 and it has been noted that the rate of mineralisation increases acutely when alkalis are administered to acidotic patients with osteomalacia.38 The long-term effects of metabolic acidosis on bone are, however, less clear and it has not been regarded as a major factor, since the correction of acidosis appears to influence renal bone disease in only a minority of patients. 39 Chronic acidosis in the absence of uraemia or hypophosphataemia-for example, chronic respiratory disease, diabetes mellitus, Gaucher's disease, is not characterised by osteomalacia.
Parathyroidectomy
Total parathyroidectomy may be associated with the development of osteomalacia when osteitis fibrosa has healed.' 10 It is interesting that, apart from patients with aluminium toxicity, a high proportion of patients with recognised osteomalacia and renal disease who fail to respond to treatment with vitamin D metabolites have had previous parathyroidectomies.'3 22 In some instances this lack of response may be related to persistent hypophosphataemia, but this is not invariably the case. The relative ease with which woven osteoid, present in hyperparathyroidism, calcifies in the absence of vitamin D (compared with lamellar osteoid) may explain the appearance of osteomalacia only after parathyroidectomy when lamellar bone is laid down. A corollary is that osteitis fibrosa may protect against osteomalacia. Otherfactors A number of years ago Yendt et al40 noted that uraemic plasma contained a factor which inhibited the calcification of rat cartilage. The nature of this uraemic factor has not been elucidated. One candidate might be pyrophosphate which is an inhibitor of calcium phosphate nucleation in vitro. Increased concentrations are found in patients with hypophosphatasia and in patients with chronic renal failure, and it is conceivable that these might cause failure of mineralisation in both conditions. In population studies there does not appear to be a clear relation between histological indices of osteomalacia and plasma pyrophosphate4' but this does not necessarily exclude a regulatory role for pyrophosphate or other inhibitors of skeletal metabolism.
TREATMENT OF OSTEOMALACIA IN CHRONIC RENAL FAILURE
The strategy of treatment should be based not only on the presence of osteomalacia or associated symptoms but also on a careful assessment of the other skeletal abnormalities present, the other consequences of disturbed mineral metabolism (Table 1) , and the mechanisms responsible for the disorder. The proposed management of the chronic renal disease itself should also be considered since, for example, therapeutic approaches may depend on the probability of subsequent transplantation.
There are a number of preventative measures which should be considered in all patients with advanced renal impairment. It is probable that the severe restriction of dietary protein, as sometimes practised, is a greater factor in inducing morbidity than it is in achieving beneficial effects. Though low protein diets restrict the amount of phosphate, this is better achieved with the use of phosphate-binding agents. Protein-deficient diets also tend to restrict the intake of vitamin C and pyridoxine which both act as essential cofactors in the formation and maturation of collagen. The relation between deficiency of these factors and osteomalacia is unclear and they may be more important in the pathogenesis of osteoporosis. Both vitamin C and vitamin B6 should be given as dietary supplements.
Treatment ofdisturbedphosphate metabolism Despite compensatory decreases in tubular reabsorption of phosphate, plasma phosphate concentrations are nearly always markedly increased in patients with severe renal impairment (Fig. 4) . The value of lowering plasma phosphate concentrations in preventing hyperparathyroid bone disease in man is uncertain but the control of plasma phosphate is important in the management and prevention of extraskeletal calcification,42 and is usually achieved by the use of phosphate-binding agents, such as aluminium hydroxide. Calcium carbonate also binds phosphate in the gut, and has potential advantages in that it corrects acidosis, increases the dietary calcium load, and enables the ingestion of aluminium to be avoided; but in practice the amounts of calcium carbonate required are large.
In order to avoid extraskeletal calcification, predialysis concentrations of plasma phosphate should be less than 2-4 mmol/1. The dialysis membrane provides a site for the loss of calcium or its incorporation into the body, but there is no evidence that the dialysate calcium concentration influences the natural history of osteomalacia.
Use ofvitamin D and related compounds A variety of vitamin D compounds is available for use in chronic renal failure. These include vitamin D2, D3, 25-OHD3, dihydrotachysterol (DHT), 1,25(OH)2-D3 and 1-alpha-OHD3. A great deal of clinical interest has focused on 1,25(OH)2-D3 and its synthetic analogue 1-alpha-OHD3 since they bypass the metabolic block caused by uraemia, but DHT is also biologically active without the necessity for l-alpha-hydroxylation by the kidney. DHT Table 4 . In general, the maximal dose which avoids hypercalcaemia decreases with time (Fig. 7) 
